Karyopharm Therapeutics (KPTI) Net Margin (2012 - 2026)
Karyopharm Therapeutics' (KPTI) quarterly Net Margin came in at 385.54% in Q4 2025, up 23602.0% YoY from N/an in Q4 2024, and up 612.59% on a QoQ basis from 75.21% in Q3 2025.
Karyopharm Therapeutics (KPTI) Net Margin (2012 - 2026) Analysis & Trends
Karyopharm Therapeutics (KPTI) has 14 years of Net Margin data on file, last reported at 385.54% in Q4 2025.
- Quarterly Net Margin rose 23602.0% year-over-year to 385.54% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 25.7% (up 2569.0% YoY) and the FY2025 annual result came in at 25.7%, up 2569.0% from the prior year.
- Net Margin climbed to 385.54% in Q4 2025, from 75.21% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 385.54% in Q4 2025 to a low of 246.84% in Q1 2021.
- A 5-year average of 42.33% and a median of 87.52% in 2022 frame the typical range for Net Margin.
- Annual changes were most pronounced in 2021 — Net Margin sank 29827 bps — and 2023, when it jumped 41726 bps.
- Tracing KPTI's Net Margin over 5 years: stood at 30.66% in 2021, then plunged by 483 bps to 117.42% in 2022, then surged by 355 bps to 299.84% in 2023, then sank by 50 bps to 149.52% in 2024, then surged by 158 bps to 385.54% in 2025.
- The last three Net Margin figures came in at 385.54% (Q4 2025), 75.21% (Q3 2025), and 98.22% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -539.31% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.90% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 12.74% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -3.12% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 12.09% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -16.51% |
| 10 | Karyopharm Therapeutics | 53.25 Mn | 53.25 Mn | 32.35 Mn | -200.48% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -200.48% |
| Dec 31, 2025 | 385.54% |
| Sep 30, 2025 | -75.21% |
| Jun 30, 2025 | -98.22% |
| Mar 31, 2025 | -78.17% |
| Dec 31, 2024 | 149.52% |
| Sep 30, 2024 | -82.70% |
| Jun 30, 2024 | 55.61% |
| Mar 31, 2024 | -112.79% |
| Dec 31, 2023 | 299.84% |
| Sep 30, 2023 | -95.83% |
| Jun 30, 2023 | -86.83% |
| Mar 31, 2023 | -88.19% |
| Dec 31, 2022 | -117.42% |
| Sep 30, 2022 | -100.50% |
| Jun 30, 2022 | -123.65% |
| Mar 31, 2022 | -86.84% |
| Dec 31, 2021 | 30.66% |
| Sep 30, 2021 | -137.47% |
| Jun 30, 2021 | -237.08% |